CVRX · CVRx
AI read · Bad for CVRX
The AI's read
Many sales representatives are new, and turnover has slowed sales in some regions. Problems with Medicare Advantage coverage also limit patient access. CVRx is improving hiring and training, but those steps have not yet shown results. Growth in steadier regions, a smaller loss, and management's confidence in Barostim's potential are positives. They do not outweigh the weaker full-year sales forecast and current sales challenges.